All posts by imreal

Pascal Rossol Promoted to Chief Commercial Officer at DFO Global


“Pascal has a talent for bringing together global teams to work more cohesively and effectively as a whole,” said President and Co-Founder Jordan Rolband.

DFO Global Performance Commerce, an industry-leading performance marketing agency, announced today that Pascal Rossol has been promoted to Chief Commercial Officer. Pascal was previously vice president for client success, where he strengthened DFO’s global e-commerce, logistics and customer service operations while expanding the company’s footprint in Europe.

In his new role, Pascal will focus on all consumer-facing eCommerce business. He will oversee activities tied to marketing, sales, product development and customer service to ensure they drive business growth, market share and customer satisfaction.

“Pascal’s success across the many facets of DFO makes him an ideal fit to ensure we align commercial strategy with organizational development,” said CEO and Co-Founder Bruce Cran.

Pascal has been part of DFO since its inception almost seven years ago. He started in DFO’s Vancouver, Canada office as a German translator and quickly moved into a creative director position, where he oversaw multilingual creative teams and coordinated global units of copywriters, designers and developers. He’s held several positions with DFO Global since then, including campaign manager, where he managed real-time eCommerce web campaigns, and business development and affiliate management roles. He is co-founder and managing director of DFO’s European operations.

“Pascal has a talent for bringing together global teams to work more cohesively and effectively as a whole,” said President and Co-Founder Jordan Rolband. “We’re excited to watch DFO grow under his leadership.”

“I’ve been fortunate to be part of our operation for a long time,” said Rossol. “To have the opportunity to inspire change, seed growth and help teams excel has been a fantastic experience. I’m excited to be at this innovative forefront with our global teams and partners.”

Pascal holds a MA from the University of Bonn in Political Science, Economics, and Media Studies as well as an MA in European Studies of Science and Technology from Aalborg and Lund University.

Share article on social media or email:

Dr. Richard E. Buckley Comments on the Rise of Earlobe Reconstruction Surgery Requests After Kelly Ripa’s Ear Reveal


Earlobe repair surgery by Dr. Richard E. Buckley

Kelly Ripa recently revealed she underwent earlobe reconstructive surgery. Dr. Richard E. Buckley discusses why torn earlobes is not the only reason clients are seeking out this surgical procedure.

Whether the earlobe is stretched purposely or accidentally over time due to heavy earrings or trauma, they can be reduced and reshaped to have pleasing, natural-looking contours, and, more excitingly, normal functionality with the ability to wear earrings again.

When people think about reconstructive earlobe surgery it’s most often thought of in relation to the early 2000 trend for “gauged” earlobes, which is a body modification where an individual would stretch their ears by continually using slightly larger jewelry to create larger than typical pierced holes. But “gauged” or purposely super-sized earlobe holes are not the only reason individuals are seeking out earlobe reconstructive surgery. “At MilfordMD there has been an increase in men and women requesting repair of their earlobes. In most cases it is due to earrings having partially or wholly torn the earlobes. Mostly not because the person purposely stretched their earlobes, but rather because of a history of wearing heavy earrings,” says Dr. Richard E. Buckley Cosmetic Surgeon and Medical Director of MilfordMD Cosmetic Dermatology Surgery & Laser Center in Milford, Penn.

During the Live with Kelly and Ryan! Fashion Finder segment on Instagram TV, Kelly Ripa shared that her earholes were torn all the way through as a result of wearing hanging earrings for years. “When this happens, it’s disheartening for patients. We frequently find out that a patient has gone fifteen to twenty years without earrings because of their torn earlobe. They are very excited to hear it can be repaired and that they can resume wearing earrings immediately following surgery,” according to Dr. Buckley.

In 2018, the ninth top cosmetic surgical procedure was earlobe surgery according to The American Society for Aesthetic Plastic Surgery revealing that it is a highly requested surgical procedure with 60% female patients and 40% male patients.

“Whether the surgery is desired because of distorted earlobes due to gauging or a result of years of heavy, hanging earrings, earlobe reconstructive surgery involves repairing the earlobe through and through. It’s not just the surface of the front of the ear that is repaired. It’s also the thickness of the ear where the scarring is removed and the backside of the ear where the ear is repaired. There is usually a bunch of scar tissue that is removed at the same time,” says Dr. Buckley.

Earlobe reconstructive surgery takes about thirty minutes per ear or one hour to repair both earlobes. The procedure uses local anesthetic, so patients are comfortable with minimal discomfort and are able to resume daily activities immediately following their surgery. Dr. Buckley recommends avoiding unclean water such as swimming pools and the ocean for two to three weeks following the surgery to minimize any infection risks.

For this type of reconstructive surgery, Dr. Richard E. Buckley taps into his surgical and artistic skills to re-shape the lobe. “The goal of this surgery is a normal contour of the earlobe. It’s important to craft the earlobes so they are aesthetically pleasing and natural-looking. The surgical process, crafting how the scarring is removed, and how the new fresh edges are put together is truly individualized. It’s in that process of individualization that the contours are restored,” says Dr. Buckley.

When reconstructing the earlobe, it’s not as simple as just sewing the top and bottom piece together. First, the healed part where the earring pulled through is removed. And the inner edges must be freshened as scar tissue can’t be pieced together. The scar tissue is removed so there is nice, fresh healthy skin to sew together. And it’s not simply two flat surfaces that are pieced together. Little steps or grooves in the shape of the letter ‘Z’ are made on each side, matched and stitched together, according to Dr. Buckley.

In the past, patients would have to wait until the repair healed before placing a new earring stud. Now, Dr. Buckley places new gold earring stud during the procedure. “What I often find is that the original earring placement is not truly symmetrical if you measure it,” says Dr. Buckley, “I make sure the new earring placements are truly symmetrical for patients.” Aftercare is a key component to a successful surgery. Patients need to turn the stud daily and keep antibiotic on the front and back side of the surgical area while it heals.

“There are many ways of crafting the earlobe repair so it is much stronger after surgery,” states Dr. Buckley. “It requires some finesse and utilization of fancy techniques which patients can’t really appreciate since it’s all inside the ear. But it makes a difference in how it heals and the future durability of the repair. This is where a surgeon’s skills and artistry come into play and that can make all the difference in the result.”

About MilfordMD Cosmetic Dermatology Surgery & Laser Center:

The MilfordMD Cosmetic Dermatology Surgery & Laser Center offers state-of-the-art highly specialized procedures in laser and cosmetic surgery and aesthetic skin care. In addition to its AAAHC nationally accredited surgical center and extensive laser surgery capabilities, MilfordMD offers physician designed skin care products for home use. Milford Pennsylvania’s MilfordMD Cosmetic Dermatology Surgery & Laser Center is sought out by patients from around the world for expertise and innovation in cosmetic treatments performed by Board Certified Physicians, Richard E. Buckley, M.D. and Marina Buckley, M.D.

MilfordMD Cosmetic Dermatology Surgery & Laser Center is located at 303 W. Harford Street, Milford, PA 18337. Tel: (570) 491-1962. For real patient video testimonials, follow MilfordMD on Instagram and Facebook, and visit our MilfordMD YouTube channel.

Share article on social media or email:



Interstate Connecting Components (ICC) to Exhibit at Sea-Air-Space


ICC exhibiting at Sea-Air-Space

ICC will be exhibiting at the Sea-Air-Space expo in National Harbor, Maryland from 4/6 through 4/8.

Interstate Connecting Components (ICC), a division of Heilind Mil-Aero and a leading distributor of military and aerospace connectors and accessories, will be exhibiting at this year’s Sea-Air-Space exposition in National Harbor, Maryland. The event is organized by the Navy League and is the largest maritime exposition in the United States.

At the show, ICC will feature a diverse range of cutting-edge military-aerospace products, including backshells, relays, naval connectors and connector accessories from leading manufacturers like Amphenol Aerospace, Amphenol Pcd, Bel Fuse/Cinch Connectivity Solutions and TE Connectivity.

“As one of the leading suppliers of mil-aero interconnects to defense contractors and commercial manufacturers, ICC is excited to exhibit at Sea-Air-Space again this year,” said Scott Jacobs, Vice President, Interstate Connecting Components. “We look forward to discussing how our diverse selection of interconnect technologies can benefit attendees.”

Interstate Connecting Components works with customers of all sizes, supporting original equipment manufacturers, prime defense contractors and subcontractors. It will have representatives at booth #1557 for the duration of the exhibit, which will be held April 6 through 8 at the Gaylord National Convention Center in National Harbor, Maryland.

About Interstate Connecting Components (ICC)

A division of Heilind Electronics, North America’s largest interconnect distributor, Interstate Connecting Components (http://www.connecticc.com) is an AS9100D-certified value-added distributor for the entire spectrum of electronic connectors, fiber optic connectors, backshells, tools, identification solutions and connector contacts. ICC specializes in the military-aerospace market and offers T’DA® 2-day assembly on 26482, 26500, 5015, D38999, M28840, M83513 and many other MIL-SPEC connector lines. Follow ICC on Facebook at facebook.com/connecticc and on Twitter at twitter.com/connecticc.

Share article on social media or email:



Two Windsor Care Centers Receive the Pinnacle Quality Insight 2020 Customer Experience Award


Pinnacle Customer Experience Award

Windsor Convalescent Center of North Long Beach, California and Encanto Palms Assisted Living in Phoenix, Arizona announced today that they are the recipients of Pinnacle Quality Insight’s 2020 Customer Experience AwardTM.

Pinnacle Quality Insight conducts thousands of monthly phone surveys to establish a comprehensive review of their clients and gauge resident satisfaction. Every year, Pinnacle awards clients who have excelled at providing a superior customer experience for their patients and residents. Out of 2,700 care providers and 150,000 customer interviews conducted each year, only those scoring in the top 15% across a 12-month average receive the award.

Clients who achieve a Customer Experience Award must score well in at least one of the following categories: Overall, satisfaction, Nursing Care, Dining Service, Quality of Food, Cleanliness, Individual Needs, Laundry Service, Communication from Facility, Response to Problems, Treatment/Dignity, Recommend Facility to Others, Recreational Activities, Professional Therapy Services, Admission Process, Overall Safety, Overall Customer Experience

“Throughout its history, Windsor has always placed a strong emphasis on ensuring that the individual needs of every resident are met,” says Mike Hurtado, Administrator at Windsor Convalescent Center of North Long Beach. “Over the course of 2019, a sampling of our residents and their families participated in monthly telephone interviews, and we are thrilled to be receive Pinnacle’s 2020 Customer Experience Award.”

“I feel privileged to serve with such amazing leaders as those at Encanto Palms Assisted Living,” adds Dr. Charles Villafranca, DHA(ABD), MSHA/HM, Administrator and Executive Director at Encanto Palms Assisted Living.

About Pinnacle Quality Insight

A customer satisfaction measurement firm with 24 years of experience in post-acute healthcare, Pinnacle conducts over 150,000 phone surveys each year and works with more than 2,500 care providers in all 50 US states, Canada and Puerto Rico.

About Windsor

Windsor Convalescent Center of North Long Beach and Encanto Palms Assisted Living are associated with Windsor healthcare centers. Windsor provides short-term and long-term healthcare, rehabilitation services and assisted living communities throughout California and Arizona. Windsor employs professionals that provide nursing, therapeutic, sub-acute and rehabilitation care to over 4,000 patients daily.

Share article on social media or email:

NFP to Access John Hancock’s New Underwriting Capabilities to Simplify the Life Insurance Purchase Process


News Image

“We are excited to be a part of the changes John Hancock is making through its alignment with Human API, as they dovetail with NFP’s overall innovation initiatives,” said Mike James, president of NFP individual solutions and PartnersFinancial.

NFP, a leading insurance broker and consultant that provides property and casualty (P&C), corporate benefits, retirement and individual solutions, today announced a strategic collaboration with John Hancock to significantly streamline the life insurance buying experience. NFP will offer a simple way for clients of NFP advisors to share access to their electronic health records (EHR) digitally and in real time.

Through its longstanding relationship with John Hancock, NFP will have access to Human API’s leading health data platform, which allows for EHR data collection from over 85 percent of US healthcare providers (health systems, hospitals, clinics and physician offices). NFP advisors will be able to leverage this platform with their clients so they can share their current and historical medical information via Human API’s digital, secure, HIPAA-compliant authorization process. This platform adds simplicity and convenience to the buying experience, allowing clients to control their personal information and give John Hancock underwriters instant access to critical medical information (lab results, medications, vital measurements and conditions). The result is a considerably shorter and more efficient case life cycle.

“We are excited to be a part of the changes John Hancock is making through its alignment with Human API, as they dovetail with NFP’s overall innovation initiatives,” said Mike James, president of NFP individual solutions and PartnersFinancial. “Instead of waiting weeks for an attending physician statement, and having potentially uncomfortable conversations with applicants about sensitive medical information, we are empowering our advisors with an easier process that ultimately creates a superior buying experience for their clients.”

“Transforming the life insurance industry by simplifying the purchase process and reducing the time from application to issue is a top priority for John Hancock,” said Susan Ghalili, vice president, underwriting transformation and chief underwriter of John Hancock Insurance. “We are always looking to work with like-minded distribution partners and it’s great to see NFP embracing new technology and offering their customers the level of service they expect in today’s digital marketplace.”

To learn more visit http://www.NFP.com.

About NFP

NFP is a leading insurance broker and consultant providing specialized property and casualty, corporate benefits, retirement and individual solutions through its licensed subsidiaries and affiliates. NFP enables client success through the expertise of over 5,600 global employees, investments in innovative technologies, and enduring relationships with highly rated insurers, vendors, and financial institutions. NFP is the 5th largest benefits broker by global revenue, 6th largest US-based privately owned broker, and 8th best place to work in insurance (Business Insurance); 10th largest property and casualty agency (Insurance Journal); and 13th largest global insurance broker (Best’s Review).

Visit NFP.com to discover how NFP empowers clients to meet their goals.

Share article on social media or email:

CrossCountry Consulting Appoints Chris Clapp to Lead Private Equity Practice


In today’s competitive deal market, we are continuing to see Private Equity firms turning to operational enhancements as a driver for value creation. CrossCountry’s suite of operational capabilities makes them an ideal partner for Private Equity.

CrossCountry Consulting, a leading business advisory firm, today announced that Chris Clapp has joined the firm as a Partner to lead their national Private Equity practice, effective immediately. Mr. Clapp will be responsible for the overall strategy, practice development, business development, and client delivery of the firm’s Private Equity accounts.

Mr. Clapp has in-depth expertise supporting Private Equity firms with implementing operational initiatives and executing strategic transactions across their portfolios. His extensive experience working on-behalf of financial sponsors will accelerate CrossCountry’s growing Private Equity practice. The firm regularly assists portfolio companies with due diligence, integrating newly acquired investments, selecting and implementing new back-office systems, improving financial reporting processes, and preparing for strategic exits.

“Part of our strategic vision, to continue to grow the firm, includes attracting talent like Chris to our team, and we are beyond thrilled to have him join us at CrossCountry,” said Dave Kay, Co-Founder and Managing Partner of CrossCountry Consulting. “His record of successes and sophisticated knowledge of the Private Equity industry will enhance the service we offer to clients.”

“In today’s competitive deal market, we are continuing to see Private Equity firms turning to operational enhancements as a driver for value creation. CrossCountry’s suite of operational capabilities, coupled with their consistent track record of delivering outstanding client service to financial sponsors, makes them an ideal partner for Private Equity,” said Chris Clapp. “I’m excited to play a role in strengthening our Private Equity practice and look forward to working in partnership with our clients and my new colleagues.”

Mr. Clapp is a certified public accountant who focuses on delivering high-quality service while developing lasting relationships with his clients. He has spent his career advising clients and leading teams on complex engagements focused on initial public offering (IPO) readiness, integration, financial reporting, technical accounting, carve-outs, due diligence, and audit readiness. Prior to joining CrossCountry Consulting, he was a Managing Director at MorganFranklin Consulting where he founded and led the Private Equity practice, as well as served as the Northeast Market and IPO Readiness Service Leader during his tenure. He began his career in the Audit and Transaction Services practices of PricewaterhouseCoopers.

To learn more about CrossCountry Consulting’s Private Equity practice, please visit: http://www.crosscountry-consulting.com/industries/private-equity/.

CrossCountry Consulting is a trusted business advisory firm that provides customized finance, accounting, human capital management, risk, operations and technology consulting services to leading organizations facing complex change. We partner with our clients to help them navigate pressing business challenges and achieve goals related to improving operations, minimizing risks and enabling future growth. For more information, visit http://www.crosscountry-consulting.com.

Share article on social media or email:

Frier Levitt Files Amicus Brief with Supreme Court on Behalf of Community Oncology Alliance and Leading Community Oncology Practices Supporting State Regulation of PBMs


The Constitution and Supreme Court precedent make clear that protecting the health and well-being of citizens is properly in the hands of the state lawmakers. It is critical that states have the right to enact laws protecting both patients and providers from PBM abuse,” Jonathan E. Levitt, Esq.

On March 2, 2020 Frier Levitt, a national boutique healthcare law firm, filed an Amicus Curiae brief with the Supreme Court of the United States in the case Rutledge v. Pharmaceutical Care Management Association on behalf of the Community Oncology Alliance (COA) and several leading community oncology practices supporting state regulation of pharmacy benefit managers (PBMs) and advocating on behalf of cancer patients and oncologists throughout the United States.

The Amicus Curiae brief brings to the Supreme Court’s attention the unique perspective of community oncology practices, articulates the various ways that PBMs have interfered with optimal cancer care, and the importance of preserving the right of the states “to protect the health and well-being of their respective citizens.”

“The Constitution and Supreme Court precedent make clear that protecting the health and well-being of citizens is properly in the hands of the state lawmakers. It is critical that states have the right to enact laws protecting both patients and providers from PBM abuse,” said Jonathan E. Levitt, Esq., a founding partner of Frier Levitt. “I am honored to have worked alongside COA and these brave practices, to ensure that the interests of cancer patients and oncologists were heard by the Supreme Court at this critical moment.”

The Petitioner in this case is the Arkansas Attorney General, Leslie Rutledge and the Respondent is powerful PBM lobbying group Pharmaceutical Care Management Association (PCMA). The specific law at issue in Rutledge is Arkansas’s Act 900, which is a comprehensive piece of legislation enacted by Arkansas in 2015 to combat improper PBM practices, including “low-ball” reimbursement tactics. Once Arkansas passed Act 900, PCMA quickly sued the State of Arkansas arguing that the legislation was preempted by ERISA. After a series of appeals by the parties, the Supreme Court determined that it would hear the merits of the case, which provided the opportunity for community oncology practices to provide their unique and important perspective on the case by filing an Amicus Curiae brief.

The Amicus Curiae brief filed on behalf of COA and six other prominent community oncology practices discusses several important issues that are often overlooked in the ongoing battle between healthcare providers, including oncologists, and PBMs, such as the advent of oral cancer drugs combined with a highly consolidated PBM landscape. The brief notes that “the increased development, availability, and use of oral cancer drugs” has “catalyzed PBMs’ shifting of patients from Community Oncology Practices to PBM-owned mail order pharmacies.” The brief further notes that based on the development of oral cancer drugs “PBMs have aggressively entered the oral cancer drug ‘market’” to the detriment of patients throughout the country. The Rutledge case is scheduled for oral argument on April 27, 2020.

Read the Amicus Curiae brief filed by Frier Levitt on behalf of COA and community oncology practices at: https://bit.ly/2PSKDu2.

About Frier Levitt

Frier Levitt is a national boutique healthcare law firm located in Pine Brook, New Jersey. Our nearly 40 attorneys bring collective experience and backgrounds in pharmacy, hospital administration, professional licensing, Attorney General actions, clinical practice, and medical billing. We provide comprehensive legal services to healthcare providers, including physician groups, laboratories, surgery and imaging centers, Compounding and Specialty Pharmacies, Outsourcing Facilities, chemical manufacturers, repackagers, wholesalers, group purchasing organizations, buying groups, and other healthcare related businesses. Frier Levitt is uniquely positioned to serve as a guide to healthcare providers, offering a broad and deep understanding of federal and state healthcare laws and regulations and the industry as a whole. Learn more at: http://www.frierlevitt.com

Share article on social media or email:

Demiurge AI Discovers the Complete Aetiology of COVID-19 and the Optimal Treatment Strategy for COVID-19


News Image

COVID-19 is fundamentally different from all the other viruses that the world has hitherto known. Treatments and policies must be rationally designed to avoid fueling the adaptive mutation and the latent infection of COVID-19.

Demiurge is responding to the global outbreak of the 2019 novel coronavirus (COVID-19) through the appropriate use of our AI platform that can make accurate drug discoveries for diseases with limited available clinical data.

Based on the deep analyses of published studies, clinical data and case reports on COVID-19 and our previously announced four AI-based discoveries for COVID-19, we hereby officially announce the 5th AI-based discovery of the complete aetiology of COVID-19 as below:


COVID-19 adopts a unique unbiased survival strategy of balancing viral replication with viral spread, in stark contrast to other viruses that typically trade off one against the other. For example, MERS coronavirus adopts a survival strategy that prioritizes viral replication over viral spread, whereas influenza viruses adopt a survival strategy that prioritizes viral spread over viral replication.


COVID-19’s course of infection bifurcates between (i) a self-limiting stage for mildly-to-moderately symptomatic patients when the unbiased survival strategy of COVID-19 is disadvantageous against the host immunity, and (ii) a self-amplifying stage for severely-to-critically ill patients when the unbiased survival strategy of COVID-19 is advantageous over the host immunity.


COVID-19 directly enhances its affinity with the functional host-cell receptor angiotensin-converting enzyme 2 (ACE2) and thus targets only stem-like cell types whose ACE2-dependent baseline activities regulate a myriad of homeostatic cellular processes that maintain genome, proteome, ion, energy, and immune system stability in a tissue-specific fashion.

  • Viral replication and egress:


COVID-19 indirectly enhances the activation of the distal promoters of the ACE2 gene in the host cells, resulting in (i) the suppression of ACE2 expression in the host cells, (ii) the hijack of the intracellular machineries of the host cells to enable viral replication and egress, and (iii) the disruption of the homeostatic functions of the host cells.


COVID-19 leverages the disrupted homeostatic functions of the host cells to create a favorable microenvironment that (i) activates the innate immune response to further reduce ACE2 expression to boost viral replication and egress, and (ii) suppresses the adaptive immune response to further reduce host cell death to sustain viral replication and egress.


COVID-19 leverages the favorable microenvironment to further enhance its inherently strong adaptive mutability as an RNA virus, thus developing robust resistance to effective but non-curative treatments that predominantly inhibit either viral replication or viral spread and making it unlikely to develop effective vaccines.


COVID-19 can flexibly switch to the latent infection mode under the pressure of strong host immunity and/or during effective but non-curative treatments. COVID-19 can also switch back to the productive infection mode when the host immunity is weakened and/or the effective but non-curative treatments are ended, resulting in inevitable rebound and frequent reinfection among asymptomatic COVID-19 carriers.


When effective but non-curative treatments switch COVID-19 to the asymptomatic latent infection mode, COVID-19 can still chronically disrupt systemic genome, proteome, ion, energy, and immune system homeostases by affecting the baseline activities of ACE2-expressing host cells in multiple organs over years. When the cumulative disruption of multi-level homeostases is sufficient to switch COVID-19 back to the symptomatic productive infection mode, COVID-19 can initiate an accelerate disease progression and trigger severe cytokine storms and fatal comorbidities.

Therefore, COVID-19 is an unprecedented coronavirus that causes both acute respiratory illnesses for symptomatic patients and chronic systemic disorders for asymptomatic carriers.

Effective but non-curative treatments or vaccines may induce a latent preservation of COVID-19 in patients instead of a complete eradication, and the adversity of latent COVID-19 will inevitably trigger a viral rebound, an accelerated progression, and an increased mortality rate.

In light of the foregoing complete aetiology of COVID-19, we hereby recommend the following optimal control & treatment strategy for COVID-19:

  • Quarantine but no treatment for asymptomatic carriers and mildly symptomatic patients to leverage the host immunity’s advantage over COVID-19 at the self-limiting stage, resulting in COVID-19 eradication.

  • Unbiased curative treatment (e.g. PI3K inhibitors) for moderately-to-severely symptomatic patients to eliminate COVID-19’s advantage over the host immunity at the self-amplifying stage, resulting in COVID-19 eradication (see our 3rd discovery here).
  • Unbiased specialized treatment (e.g. topoisomerase I inhibitors + topoisomerase II inhibitors) for critically ill patients to reduce mortality (see our 4th discovery here).

In pandemic settings, public interest in treatment availability and commercial interest in marketing exclusivity are usually misaligned, but we have no doubt that public interest must be prioritized because lives matter above all else.

We have thus chosen to announce those discoveries to the public first without any delay in either applying for patent protection in secret or working with biopharmaceutical companies in private, so as to waive commercial interests once for all to speed up cross-border concerted efforts to solve the unprecedented global crisis posed by COVID-19.

About Demiurge Technologies AG

Demiurge Technologies is a research-based AI-biopharmaceutical company that transforms publicly available life science data into precise disease models in areas with unmet medical needs. The company pioneers a self-correcting scientific approach that validates disease models with the accuracy of AI-based predictions of phase 3 clinical trial outcomes. The company also pioneers a self-sustaining business that commercializes disease models by accelerating the AI-based discovery and development of innovative medicines. Demiurge started in 2016 with headquarters in Switzerland.

AI has been an emerging powerful approach to deeper disease understanding and faster drug discovery, yet it must be put to the most rigorous test to prove its worth under public scrutiny. Demiurge has predicted the outcomes of more than 90 phase 3 clinical trials across multiple therapeutic areas and achieved more than 80% accuracy. Furthermore, we have been inviting the public to witness our future predictions of clinical trial outcomes on Twitter (@DemiurgeTech).

Therefore, we officially put forward AI-based discoveries of the complete aetiology of COVID-19 and the candidate treatments for COVID-19 as scientific hypotheses only and invite the world to validate their potential to solve the unprecedented global crisis posed by COVID-19.

Media Inquiry:

covid2019@demiurge.technology

Share article on social media or email:



Octopai Announces Support of Tabular on Azure Analysis Services, Netezza and Vertica as well as Expanded Support of OLAP Cubes for Better BI Intelligence


Octopai, a leader in metadata management automation for BI & Analytics, announces today that the company has added support for Tabular on Azure Analysis Services, IBM’s Netezza, Vertica, and has expanded its support of OLAP cubes to enable organizations to understand their complete data flow to get full control over their data assets through automated data lineage and discovery.

With approximately 35% of enterprise reports residing on Microsoft’s Online Analytical Processing (SSAS – OLAP) cube, largely unsupported by data lineage tools, enterprises are increasingly frustrated by their extremely limited visibility of the data journey. To address this issue, Octopai has added advanced capabilities in its support of OLAP (full coverage of SSAS, both tabular models and OLAP cubes), enabling those organizations who rely on analysis tools to finally enjoy complete data lineage for reports based on OLAP cubes as well as MDX (MultiDimensional eXpressions) statements.

Additionally, with IBM’s recent announcement of Netezza’s end of life, many Netezza users are looking to migrate their data over to another database (DWH). Now Octopai can assist organizations using Netezza with their migration, specifically to help them quickly and easily find and understand their data so they know what to move to their new system and what to forego. Other newly supported systems include Vertica and Azure Analysis Services. Octopai will announce coverage of Ab Initio, Azure Data Factory, Talend, Amazon Redshift and Snowflake in the coming months to bring ongoing value to the BI & Analytics domain.

“Once blind in the face of their data, we are very excited to offer our cube customers expanded support of OLAP so that they can finally see the entire data journey with automated data lineage,” said Gal Ziton, CTO. “We are proud to continuously add ongoing capabilities for more and more customers using varying platforms and systems to provide a unified view and map of their data.”

To find out more about Octopai, visit http://www.octopai.com.

About Octopai:

Octopai was founded in 2015 by experienced BI professionals who had a need for time-saving and simplifying solutions. Octopai’s SaaS platform automates metadata management and analysis, enabling enterprise BI groups to quickly, easily and accurately find and understand their data. Octopai is empowering BI with complete data lineage, discovery and automated business glossary capabilities for superior BI operations, data governance, and data quality. The company was recognized as a Gartner Cool Vendor for Data Science and Machine Learning in 2018 and their investors include North First Ventures, Gefen Capital and iAngels.

Share article on social media or email:

Gareda Home Care Services Selects CareAcademy as their Trusted Training Provider for Thousands of Caregivers


Our partnership with CareAcademy allows us to go beyond just an online training program and focus on growing our business by investing in the learning, upskilling, and development of our most precious resource, our caregivers.

Gareda Home Care Services, one of the largest independently-owned, non-medical home care agencies in Illinois, employing over 2500 Home Care Aides, announced today they’ve selected CareAcademy as their trusted caregiver training solution.

Gareda has been serving Illinois for nearly 40 years, providing exceptional home care services to its clients. Gareda employs dedicated Home Care Aides that are thoroughly evaluated and screened and undergo extensive training. Gareda switched from an online training provider to CareAcademy’s learning and development platform because of CareAcademy’s demonstrated ability to improve onboarding and provide superior technology, content, and service. CareAcademy will serve as the platform to deliver interpersonal, compliance, and caregiver skills education in support of Gareda’s in-home care training programs.

“Our partnership with CareAcademy allows us to go beyond just an online training program and focus on growing our business by investing in the learning, upskilling, and development of our most precious resource, our caregivers. CareAcademy’s superior but simple technology, content, and service allows our business to continue to scale while providing the highest quality care to our clients,” said Ella Grays, Chief Executive Officer of Gareda. “As innovators in this space, we know that better technology and high-quality classes will help us as we grow. To that end, we’re extremely excited to provide CareAcademy’s high-quality training to our thousands of caregivers, enabling them to provide top notch care to our clients.”

“Gareda’s leadership team is a pillar of the Illinois community at large, and particularly the Illinois Association of Community Care Program Homecare Providers community. We’re thrilled to be the new solution of choice to help Gareda streamline many HR functions and prepare the right quality caregiver to work with any client, at any time, to meet the growing demand,” says Helen Adeosun, CEO and Co-founder of CareAcademy. “Our best-in-class software and learning modules enable owners and managers to upskill workers for health needs and even certify new health workers in a range of skills to reduce their shortage of qualified workers.”

CareAcademy helps home care agencies grow faster and effortlessly maintain compliance with engaging online caregiver learning and easy-to-use technology. CareAcademy has been shown to reduce caregiver onboarding time by up to 60%, driving higher revenues for home care agencies. CareAcademy offers high-quality caregiver training on an easy-to-use platform that automatically assigns the right training at the right time. Caregivers take engaging, bite-sized video classes on their smartphones. As a result of the class accessibility, platform features like text and email reminders, and simple but powerful technology, classes have a 90%+ completion rate. Home care agencies have the opportunity to access nearly 160 hours of mobile-friendly video training to meet state requirements, upskill their caregivers, and quickly onboard caregivers for new clients.

About CareAcademy

Founded by caregivers, CareAcademy creates online training that empowers senior care professionals to deliver the highest caliber of service and improve the lives of older adults. Over 70,000 caregivers are learning and growing professionally through CareAcademy. Coupled with its automated training compliance dashboard, CareAcademy is an end-to-end, scalable training solution that transforms home care businesses into efficient industry leaders. To learn more, visit: http://www.CareAcademy.com.

About Gareda

Gareda has been serving Illinois with pride, care and expertise since 1981. Gareda’s quality in-home care services enable individuals to maintain in the comfort of their own home. Gareda upholds the worth and dignity of its diverse community of clients all while maintaining a family of dedicated employees by fostering an environment that integrates teamwork, integrity and unwavering professionalism. To learn more, visit: http://www.Gareda.com/

Share article on social media or email: